文献速递系统性红斑狼疮

系统性红斑狼疮患者停用吗替麦考酚酯:一项多中心、开放标签、随机对照试验

Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.
PubMed 文献 · Lancet Rheumatol · 2024-01-29

这项在美国19个中心开展的多中心、开放标签、随机对照试验纳入病情稳定的系统性红斑狼疮(SLE)患者,比较停用吗替麦考酚酯(撤药组)与维持基线剂量(维持组)至第60周临床显著疾病再激活的风险。撤药组18%(9/51)vs 维持组10%(5/49)出现临床显著疾病再激活,撤药所致风险估计增加7%(单侧85%置信上限15%),作者认为撤药并非显著劣于维持。

要点

  • 病情稳定SLE患者停用吗替麦考酚酯后第60周临床显著疾病再激活为18%(9/51)vs 维持组10%(5/49)。
  • 撤药组疾病再激活风险18%(95%CI 10-32)vs 维持组11%(95%CI 5-24),撤药所致风险估计增加7%(单侧85%置信上限15%)。
  • 维持组感染更常见(32[64%])vs 撤药组(24[46%]),不良事件两组相似(维持组45[90%] vs 撤药组46[88%])。

核心结论

  • 作者认为停用吗替麦考酚酯并非显著劣于维持治疗。
  • 作者认为疾病再激活率及撤药所致风险增加的估计值可帮助临床医生对稳定SLE患者停用吗替麦考酚酯做出知情决策。

研究设计与样本

  • 多中心、开放标签、随机对照试验,在美国19个中心开展,纳入18至70岁符合ACR 1997 SLE标准且筛选时临床SLEDAI评分低于4分的患者。
  • 吗替麦考酚酯因肾脏适应证启用者需稳定或减量至少2年,因非肾脏适应证启用者需稳定或减量至少1年。
  • 参与者按1:1随机分配至撤药组(12周内逐渐减停吗替麦考酚酯)或维持组(维持基线剂量1-3g/天共60周),采用适应性随机分配确保研究 site、肾脏与非肾脏疾病、基线吗替麦考酚酯剂量(≥2g/天 vs <2g/天)组间平衡。
  • 主要终点为随机分配后第60周前需增加剂量或新免疫抑制治疗的临床显著疾病再激活,在改良意向治疗人群(所有开始接受研究提供吗替麦考酚酯的随机分配参与者)中分析,采用基于估计的方法评价非劣效性。
  • 2013年11月6日至2018年4月27日筛查123例,102例随机分配至维持组(n=50)或撤药组(n=52);改良意向治疗分析纳入100例(维持组49例,撤药组51例),其中女性84例(84%)、男性16例(16%),白人40例(40%)、黑人41例(41%),有狼疮肾炎病史76例(76%),平均年龄42岁(SD 12.7)。

主要发现

  • 第60周时撤药组51例中9例(18%)出现临床显著疾病再激活,维持组49例中5例(10%)出现。
  • 临床显著疾病再激活风险维持组为11%(95%CI 5-24),撤药组为18%(95%CI 10-32)。
  • 撤药所致临床显著疾病再激活风险估计增加7%(单侧85%置信上限15%)。
  • 不良事件发生率维持组45/50例(90%)与撤药组46/52例(88%)相似。
  • 感染在吗替麦考酚酯维持组更常见(32/50例[64%])vs 撤药组(24/52例[46%])。

关键数值与推荐

  • 作者结论为停用吗替麦考酚酯并非显著劣于维持治疗,未给出推荐等级。
  • 撤药组临床显著疾病再激活18%(9/51)vs 维持组10%(5/49)。
  • 撤药所致风险估计增加7%(单侧85%置信上限15%)。
  • 维持组感染32/50例(64%)vs 撤药组24/52例(46%)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为疾病再激活率及撤药所致风险增加的估计值可帮助临床医生对稳定SLE患者停用吗替麦考酚酯做出知情决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycophenolate mofetil is an immunosuppressant commonly used to treat systemic lupus erythematosus (SLE) and lupus nephritis. It is a known teratogen associated with significant toxicities, including an increased risk of infections and malignancies. Mycophenolate mofetil withdrawal is desirable once disease quiescence is reached, but the timing of when to do so and whether it provides a benefit has not been well-studied. We aimed to determine the effects of mycophenolate mofetil withdrawal on the risk of clinically significant disease reactivation in patients with quiescent SLE on long-term mycophenolate mofetil therapy. METHODS: This multicenter, open-label, randomised trial was conducted in 19 centres in the USA. Eligible patients were aged between 18 and 70 years old, met the American College of Rheumatology (ACR) 1997 SLE criteria, and had a clinical SLEDAI score of less than 4 at screening. Mycophenolate mofetil therapy was required to be stable or decreasing for 2 years or more if initiated for renal indications, or for 1 year or more for non-renal indications. Participants were randomly allocated in a 1:1 ratio to a withdrawal group, who tapered off mycophenolate mofetil over 12 weeks, or a maintenance group who maintained their baseline dose (1-3g per day) for 60 weeks. Adaptive random allocation ensured groups were balanced for study site, renal versus non-renal disease, and baseline mycophenolate mofetil dose (≥2 g per day vs <2 g per day). Clinically significant disease reactivation by week 60 following random allocation, requiring increased doses or new immunosuppressive therapy was the primary endpoint, in the modified intention-to-treat population (all randomly allocated participants who began study-provided mycophenolate mofetil). Non-inferiority was evaluated using an estimation-based approach. The trial was registered at ClinicalTrials.gov (NCT01946880) and is completed. FINDINGS: Between Nov 6, 2013, and April 27, 2018, 123 participants were screened, of whom 102 were randomly allocated to the maintenance group (n=50) or the withdrawal group (n=52). Of the 100 participants included in the modified intention-to-treat analysis (49 maintenance, 51 withdrawal), 84 (84%) were women, 16 (16%) were men, 40 (40%) were White, 41 (41%) were Black, and 76 (76%) had a history of lupus nephritis. The average age was 42 (SD 12·7). By week 60, nine (18%) of 51 participants in the withdrawal group had clinically significant disease reactivation, compared to five (10%) of 49 participants in the maintenance group. The risk of clinically significant disease reactivation was 11% (95% CI 5-24) in the maintenance group and 18% (10-32) in the withdrawal group. The estimated increase in the risk of clinically significant disease reactivation with mycophenolate mofetil withdrawal was 7% (one-sided upper 85% confidence limit 15%). Similar rates of adverse events were observed in the maintenance group (45 [90%] of 50 participants) and the withdrawal group (46 [88%] of 52 participants). Infections were more frequent in the mycophenolate mofetil maintenance group (32 [64%]) compared with the withdrawal group (24 [46%]). INTERPRETATIONS: Mycophenolate mofetil withdrawal is not significantly inferior to mycophenolate mofetil maintenance. Estimates for the rates of disease reactivation and increases in risk with withdrawal can assist clinicians in making informed decisions on withdrawing mycophenolate mofetil in patients with stable SLE. FUNDING: The National Institute of Allergy and Infectious Diseases and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Chakravarty EF, Utset T, Kamen DL, et al. Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. Lancet Rheumatol. 2024. PMID: 38301682. doi:10.1016/S2665-9913(23)00320-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。